OncoTherapy Science (4564.T) Stock Price
OncoTherapy Science Price
Revenue has compounded at 0.0% per year over the past 19 years to 808.53 M JPY. Earnings per share have grown at 66.0% per year over the last 3 years. OncoTherapy Science's net margin stands at -112.6%, up from -222.9% several years earlier.
OncoTherapy Science stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
OncoTherapy Science business model & stock analysis
Frequently asked questions about OncoTherapy Science
The business model of OncoTherapy Science Inc revolves around developing cutting-edge therapies for cancer treatment. The company focuses on leveraging its innovative technologies and expertise in molecular biology to discover and develop novel drugs targeting cancer cells. OncoTherapy Science Inc aims to improve patient outcomes by advancing precision medicine through personalized therapies. By analyzing the genetic makeup of tumor cells, the company identifies specific targets and develops therapeutics to inhibit their growth. With a strong emphasis on research and development, OncoTherapy Science Inc strives to bring breakthrough treatments to market, offering hope to cancer patients worldwide.
OncoTherapy Science Inc is primarily active in the biotechnology industry.
The main competitors of OncoTherapy Science Inc in the market include pharmaceutical companies such as Pfizer, Merck & Co., and Novartis.
OncoTherapy Science Inc is a leading biotechnology company specializing in innovative cancer therapies. With a rich history spanning several successful years, OncoTherapy Science Inc has consistently demonstrated its commitment to revolutionizing cancer treatment through cutting-edge research and development. The company has a strong background in targeted therapies, utilizing advanced techniques to understand and combat the complex mechanisms of cancer. OncoTherapy Science Inc prioritizes patient-centric approaches, seeking to improve clinical outcomes and ultimately save lives. Their dedicated team of scientists and researchers are relentlessly working towards discovering breakthrough treatments for various types of cancer, cementing their position as a trusted leader in the field of oncology.
OncoTherapy Science Inc, a leading biotechnology company, has achieved several significant milestones in its journey. The company's dedication to cutting-edge research and innovation has resulted in remarkable achievements. OncoTherapy Science Inc has successfully developed and commercialized groundbreaking therapies for various types of cancers, revolutionizing the treatment landscape. Moreover, the company has received multiple accolades for its exceptional contributions to the field of oncology. OncoTherapy Science Inc's relentless pursuit of excellence has positioned it as a key player in the fight against cancer, making it a trusted name in the industry. With numerous achievements under its belt, OncoTherapy Science Inc continues to pave the way for advancements in cancer treatment.
OncoTherapy Science Inc is primarily present in Japan.
OncoTherapy Science Inc represents values of innovation, integrity, and commitment to advancing cancer treatments. The company's corporate philosophy revolves around conducting groundbreaking research to develop effective therapies for oncology patients. With a focus on precision medicine, OncoTherapy Science Inc aims to deliver personalized and targeted treatments for individuals battling cancer. Their dedication to scientific excellence, collaboration with key stakeholders, and patient-centric approach sets them apart in the field of oncology. OncoTherapy Science Inc's commitment to improving patient outcomes and revolutionizing cancer care aligns with their vision of becoming a global leader in precision oncology.
Converted at the current exchange rate, the OncoTherapy Science share trades at 0.10 EUR (17.00 JPY).
The OncoTherapy Science share (4564.T) is listed on 3 stock exchanges, including: Tokio (JPX) (4564.T), Frankfurt (30O.F), München (30O.MU).
OncoTherapy Science Inc. is a leading biopharmaceutical company focused on the development of innovative cancer therapies. It offers a comprehensive portfolio of therapeutics and diagnostics to improve the treatment and cure of cancer patients worldwide. The company is divided into different divisions to enable effective development of cancer therapies, including research and development, production, marketing, and distribution of cancer drugs. The research and development department of OncoTherapy Science Inc. consists of a team of scientists and researchers who focus on identifying new therapeutic targets and developing innovative therapeutics. The research department has already made significant advances in the field of personalized medicine. OncoTherapy Science Inc. provides a wide range of products to offer better therapy options for cancer patients, including innovative antibody-based therapeutics, including immunotherapies, cytokines, antibody conjugates, mono- and polyclonal antibodies. The company also works on the development of diagnostics to enhance the effectiveness of therapy options, offering tests and diagnostic instruments that improve the accuracy of diagnosis and help patients choose the best possible therapy option. OncoTherapy Science Inc. also has a production department that utilizes modern technologies and automated production lines. The production facilities are set up according to the latest GMP standards to ensure that the products are of the highest quality and purity and comply with FDA regulations. The company markets and distributes its products worldwide through a network of partners and distributors. It has branches in different countries and collaborations with leading research institutions and universities around the world to support its research and development. In summary, OncoTherapy Science Inc. is a company focused on the research, development, and marketing of cancer therapeutics and diagnostics. It aims to provide better treatment options for cancer patients worldwide and has already made significant progress. With its wide range of innovative products, modern production facility, and strong research and development program, OncoTherapy Science Inc. is a leading company in cancer research and therapy.
The revenue of OncoTherapy Science is 808.53 M JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of OncoTherapy Science is -910.64 M JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of OncoTherapy Science is currently -7.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the OncoTherapy Science stock.
The price-to-sales ratio (P/S) of OncoTherapy Science is currently 8.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the OncoTherapy Science stock.
The Eulerpool Quality Score for OncoTherapy Science is 3/10.
The ISIN of OncoTherapy Science is JP3202150003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of OncoTherapy Science is 726692. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of OncoTherapy Science is 4564.T. The ticker symbol is used to trade OncoTherapy Science shares on the stock exchange.
OncoTherapy Science stock
OncoTherapy Science Peer Group
OncoTherapy Science Ticker
OncoTherapy Science FIGI
All fundamentals and in-depth analysis of OncoTherapy Science
Our stock analysis for OncoTherapy Science stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoTherapy Science. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.